Do analysts rate BYSI or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BYSI or XCUR more profitable?

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Exicure N/A -179.41% -64.37%

Do analysts recommend XCUR or MCRB?

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 116.56%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is XCUR or MCRB more profitable?

Seres Therapeutics' return on equity of -130.29% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Seres Therapeutics N/A -130.29% -35.35%

Does the media favor XCUR or MCRB?

In the previous week, Seres Therapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Exicure. Seres Therapeutics' average media sentiment score of 1.03 beat Exicure's score of 0.63 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MNOV or XCUR?

MediciNova currently has a consensus target price of $8.33, suggesting a potential upside of 449.69%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MNOV or XCUR?

Exicure has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediciNova $410K 181.99 -$12M -$0.23 N/A Exicure $500K 25.61 -$4.95M -$1.55 N/A

Is MNOV or XCUR more profitable?

Exicure has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,962.98% -27.28% -25.24% Exicure N/A -179.41% -64.37%

Does the media refer more to MNOV or XCUR?

In the previous week, MediciNova had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for MediciNova and 3 mentions for Exicure. Exicure's average media sentiment score of 0.63 beat MediciNova's score of 0.52 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CYPH or XCUR?

Cypherpunk Technologies presently has a consensus price target of $0.90, suggesting a potential upside of 33.43%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Cypherpunk Technologies is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CYPH or XCUR more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Exicure N/A -179.41% -64.37%

Do analysts rate CING or XCUR?

Cingulate currently has a consensus target price of $27.33, suggesting a potential upside of 370.45%. Given Cingulate's stronger consensus rating and higher possible upside, equities analysts plainly believe Cingulate is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CING or XCUR more profitable?

Exicure's return on equity of -179.41% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Exicure N/A -179.41% -64.37%

Does the media prefer CING or XCUR?

In the previous week, Cingulate and Cingulate both had 3 articles in the media. Cingulate's average media sentiment score of 1.05 beat Exicure's score of 0.63 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exicure (XCUR) Competitors

$2.01 -0.07 (-3.37%)

As of 12:41 PM Eastern

Compare

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

Should you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include BeyondSpring (BYSI), Seres Therapeutics (MCRB), MediciNova (MNOV), Cypherpunk Technologies (CYPH), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry.

How does Exicure compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

BeyondSpring has higher revenue and earnings than Exicure. BeyondSpring is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	40.30	-$1.01M	-$0.14	N/A
Exicure	$500K	25.61	-$4.95M	-$1.55	N/A

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, meaning that its stock price is 253% more volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Exicure	N/A	-179.41%	-64.37%

In the previous week, Exicure had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Exicure and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Exicure's score of 0.63 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Exicure	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BeyondSpring beats Exicure on 7 of the 12 factors compared between the two stocks.

How does Exicure compare to Seres Therapeutics?

Exicure (NASDAQ:XCUR) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 116.56%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Seres Therapeutics has higher revenue and earnings than Exicure. Seres Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	25.61	-$4.95M	-$1.55	N/A
Seres Therapeutics	$790K	96.19	$5.70M	-$5.17	N/A

Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Seres Therapeutics	N/A	-130.29%	-35.35%

In the previous week, Seres Therapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Exicure. Seres Therapeutics' average media sentiment score of 1.03 beat Exicure's score of 0.63 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Seres Therapeutics beats Exicure on 11 of the 15 factors compared between the two stocks.

How does Exicure compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market.

9.9% of MediciNova shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MediciNova currently has a consensus target price of $8.33, suggesting a potential upside of 449.69%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, MediciNova had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for MediciNova and 3 mentions for Exicure. Exicure's average media sentiment score of 0.63 beat MediciNova's score of 0.52 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Exicure	N/A	-179.41%	-64.37%

Exicure has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	181.99	-$12M	-$0.23	N/A
Exicure	$500K	25.61	-$4.95M	-$1.55	N/A

Summary

MediciNova beats Exicure on 9 of the 17 factors compared between the two stocks.

How does Exicure compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Cypherpunk Technologies has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Exicure had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Exicure's score of 0.63 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Exicure	Positive

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Exicure	N/A	-179.41%	-64.37%

Cypherpunk Technologies has higher earnings, but lower revenue than Exicure. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Exicure	$500K	25.61	-$4.95M	-$1.55	N/A

Cypherpunk Technologies presently has a consensus price target of $0.90, suggesting a potential upside of 33.43%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Cypherpunk Technologies is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cypherpunk Technologies beats Exicure on 8 of the 14 factors compared between the two stocks.

How does Exicure compare to Cingulate?

Cingulate (NASDAQ:CING) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Cingulate and Cingulate both had 3 articles in the media. Cingulate's average media sentiment score of 1.05 beat Exicure's score of 0.63 indicating that Cingulate is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.3% of Cingulate shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cingulate currently has a consensus target price of $27.33, suggesting a potential upside of 370.45%. Given Cingulate's stronger consensus rating and higher possible upside, equities analysts plainly believe Cingulate is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cingulate has a beta of -0.85, suggesting that its stock price is 185% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, suggesting that its stock price is 253% more volatile than the broader market.

Exicure has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Exicure	$500K	25.61	-$4.95M	-$1.55	N/A

Exicure's return on equity of -179.41% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Exicure	N/A	-179.41%	-64.37%

Summary

Exicure beats Cingulate on 9 of the 13 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.80M	$3.66B	$6.80B	$12.58B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.30	21.54	27.48	25.45
Price / Sales	25.61	343.84	541.47	103.18
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	3.24	8.73	10.97	6.65
Net Income	-$4.95M	$23.87M	$3.57B	$336.83M
7 Day Performance	-25.28%	3.76%	2.80%	3.00%
1 Month Performance	-39.64%	3.79%	1.93%	0.56%
1 Year Performance	-67.05%	67.44%	36.49%	30.42%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	1.0028 of 5 stars	$2.01 -3.4%	N/A	-70.5%	$12.80M	$500K	N/A	50	News Coverage Gap Down
BYSI BeyondSpring	0.2578 of 5 stars	$1.62 +0.4%	N/A	-25.5%	$66.45M	$1.75M	N/A	80
MCRB Seres Therapeutics	3.9536 of 5 stars	$6.83 -3.2%	$17.00 +149.1%	-29.0%	$66.07M	$790K	N/A	330	Positive News Short Interest Decrease
MNOV MediciNova	3.2502 of 5 stars	$1.33 -2.2%	$8.33 +526.6%	+0.8%	$65.46M	$596.64K	N/A	10	News Coverage Short Interest Decrease
CYPH Cypherpunk Technologies	2.5731 of 5 stars	$0.61 -6.5%	N/A	+106.2%	$64.95M	N/A	N/A	40	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

How does Exicure compare to BeyondSpring?

Summary

How does Exicure compare to Seres Therapeutics?

Summary

How does Exicure compare to MediciNova?

Summary

How does Exicure compare to Cypherpunk Technologies?

Summary

How does Exicure compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

How does Exicure compare to BeyondSpring?

Which has better earnings and valuation, BYSI or XCUR?

Do insiders and institutionals hold more shares of BYSI or XCUR?

Which has more risk and volatility, BYSI or XCUR?

Is BYSI or XCUR more profitable?

Does the media refer more to BYSI or XCUR?

Do analysts rate BYSI or XCUR?

Summary

How does Exicure compare to Seres Therapeutics?

Do analysts recommend XCUR or MCRB?

Which has better valuation & earnings, XCUR or MCRB?

Which has more risk & volatility, XCUR or MCRB?

Do institutionals and insiders believe in XCUR or MCRB?

Is XCUR or MCRB more profitable?

Does the media favor XCUR or MCRB?

Summary

How does Exicure compare to MediciNova?

Which has more volatility and risk, MNOV or XCUR?

Do insiders and institutionals hold more shares of MNOV or XCUR?

Do analysts rate MNOV or XCUR?

Does the media refer more to MNOV or XCUR?

Is MNOV or XCUR more profitable?

Which has higher valuation & earnings, MNOV or XCUR?

Summary

How does Exicure compare to Cypherpunk Technologies?

Which has more risk & volatility, CYPH or XCUR?

Do insiders & institutionals hold more shares of CYPH or XCUR?

Does the media refer more to CYPH or XCUR?

Is CYPH or XCUR more profitable?

Which has preferable earnings and valuation, CYPH or XCUR?

Do analysts rate CYPH or XCUR?

Summary

How does Exicure compare to Cingulate?

Does the media prefer CING or XCUR?

Do institutionals and insiders hold more shares of CING or XCUR?

Do analysts rate CING or XCUR?

Which has more volatility & risk, CING or XCUR?

Which has stronger valuation and earnings, CING or XCUR?

Is CING or XCUR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools